What is Brief History of Terumo Company?

Terumo Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

How did Terumo grow from a thermometer maker to a global medtech leader?

Founded in 1921 to localize clinical thermometers, Terumo now supplies catheters, stents, blood systems and consumables to over 160 countries. Its 1973 launch of disposable syringes set a quality and infection-control benchmark that shaped future hospital products.

Terumo reports consolidated revenue of approximately ¥1.03 trillion (FY2023, year ended Mar 2024) with overseas sales above 75%, organized across Cardiac & Vascular, Blood & Cell Technologies, and Medical Care Solutions under the GS26 plan.

What is Brief History of Terumo Company? From Sekisen Ken-onki Corporation in Tokyo to a diversified medtech group—key milestones include Japan’s first domestic clinical thermometer, mass-produced disposable syringes in 1973, global expansion, and ongoing product innovation. See Terumo Porter's Five Forces Analysis

Terumo was founded on September 17, 1921, in Tokyo by Japanese physicians and engineer Kotaro Terumo’s circle to produce reliable clinical thermometers domestically, addressing scarcity and inconsistent accuracy from imports.

Founding Story

Physicians from the Japan Medical Association and engineers launched a precision glass and mercury thermometry venture to secure clinical-grade instruments for hospitals and clinics.

• Founded on September 17, 1921 in Tokyo to address imported thermometer shortages
• Initial product: domestically produced clinical thermometer (Ken-onki) calibrated to international standards
• Early funding: physician-backed and local bank finance; operations began in a small Tokyo workshop
• Original model: design, manufacture, quality assurance and distribution through medical associations

Early emphasis on accuracy and local supply laid the groundwork for Terumo company history and Terumo corporation overview; this founding and origins narrative explains how Terumo product evolution and Terumo historical timeline medical devices began, leading to later moves into blood management and cardiovascular devices. See Marketing Strategy of Terumo for related context.

Terumo SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Early Growth and Expansion of Terumo saw the firm evolve from glass instrument maker into a diversified medical-device leader, scaling production, entering disposables and cardiovascular technologies, and expanding globally through targeted acquisitions and factory growth.

1920s–1950s: Foundation and Postwar Rebuild

Founded in the 1920s as a glass-instrument maker, the company scaled sphygmomanometers and thermometers through the 1920s–1930s and by the late 1930s served hospitals and public health agencies. Postwar reconstruction in the 1940s–1950s restored facilities and introduced standardized quality systems that enabled mass production and reliability across medical devices.

1960s–1970s: Entry into Single-Use Disposables

In the 1960s–1970s the firm entered single-use disposables, launching IV catheters and, in 1973, disposable hypodermic syringes that captured market share during Japan’s infection-control drive. The Ashitaka factory in Shizuoka expanded sterile manufacturing capacity to meet rising domestic demand.

1980s–1999: Cardiovascular Push and U.S./EU Expansion

During the 1980s Terumo entered cardiovascular intervention with percutaneous catheters and guidewires and began exporting to the U.S. and Europe via sales subsidiaries. The 1999 acquisition of 3M’s cardiopulmonary business assets accelerated entry into perfusion and oxygenation, broadening the company’s cardiovascular portfolio.

2000s–2011: Strategic Acquisitions

Key acquisitions included U.K.-based Vascutek in 2002 and a majority stake in MicroVention in 2006, adding vascular grafts, coil embolization and neurovascular access. The transformative purchase of CaridianBCT for about $2.6 billion in 2011 created Terumo BCT and positioned the company as a global leader in blood component and apheresis technologies.

From the 2010s, product evolution emphasized drug-eluting stents, radial-access devices (Glidesheath) and closure systems; manufacturing footprint expanded to Vietnam, the Philippines and Costa Rica to diversify supply and reduce costs, supporting global expansion and stronger margins.

Market reception favored Terumo where procedural innovation—especially radial-first cardiology—and engineering precision differentiated the firm versus larger competitors, prompting a strategic focus on neurovascular, access and blood technologies to balance scale and margin. See further market context in Target Market of Terumo.

Terumo PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Milestones, Innovations and Challenges of the Terumo company history track a shift from Japan’s first domestically produced clinical thermometer in 1921 to a global medical devices leader with diversified platforms in Cardiac & Vascular, BCT and Medical Care.

Terumo innovations span disposable syringes and thermometers to advanced neurovascular coils and flow‑diverters, radial‑access consumables, drug‑eluting stents and automated cell therapy platforms.

Disposable Syringes

The 1973 mass production of disposable hypodermic syringes dramatically improved infection control and set a foundation for Terumo product evolution globally.

Radial Access Tools

Glidewire and Glidesheath Slender technologies established Terumo as a leader in radial access, reducing complications and procedure times in cardiology.

Neurovascular Devices

Integration with MicroVention enabled next‑generation coils and flow‑diverters for aneurysm treatment, advancing Terumo history in cardiovascular devices development.

Vascular Grafts

Vascutek acquisition created aortic and vascular graft platforms, later unified under Terumo Aortic to offer endovascular and surgical solutions.

Cell Therapy Automation

Terumo BCT delivered the Spectra Optia apheresis platform and automated cell processing systems that underpin contemporary cell therapy manufacturing.

Drug‑Eluting Stents

The Ultimaster stent series represents Terumo’s push into specialty interventional cardiology amid a stent commoditization landscape.

Key challenges include pricing pressure from group purchasing organizations, stent commoditization and tighter regulatory regimes such as the EU MDR, compounded by foreign‑exchange volatility.

Pricing Pressure

Group purchasing and commoditization compressed margins; Terumo shifted toward higher‑value specialty interventions and disciplined pricing strategies.

Regulatory Scrutiny

EU MDR and global regulatory tightening required increased compliance spend and longer device approvals, influencing product launch timelines.

Supply Chain Volatility

Pandemic era logistics disruptions prompted supply chain diversification and manufacturing in lower‑cost regions to stabilize supply and costs.

M&A and Portfolio Focus

Terumo pursued targeted acquisitions like CaridianBCT and MicroVention while optimizing manufacturing footprint to maintain competitiveness.

Financial Discipline

Revenue growth to ~¥1.03 trillion in 2023–2024 and 6–7% R&D intensity illustrate a focus on R&D investment and margin recovery.

Strategic Lessons

Compete where engineering precision and procedural innovation matter; diversify across Cardiac & Vascular, BCT and Medical Care to smooth cycles.

For further context on market peers and competitive positioning see Competitors Landscape of Terumo

Terumo Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Timeline and Future Outlook of Terumo company history: concise chronology from its 1921 founding through key product, M&A, and global-expansion milestones, concluding with GS26 targets through FY2026/27 and strategic priorities in neurovascular, blood management, and cell-therapy automation.

Strategic Financial Targets (GS26)

Targets mid-single-digit organic revenue CAGR through FY2026/27, operating margin expansion toward the high teens, and sustained free cash flow to fund 6–7% of sales in R&D and selective M&A.

R&D and Capex Focus

Capex prioritized for neurovascular coils and stents, drug-device combinations, and automation for cell therapy manufacturing to support long-term growth.

Market and Product Drivers

Demographics and clinical trends—aging populations, minimally invasive procedures, and growth in cell and gene therapies—support Terumo medical devices history and product evolution priorities.

Geographic Expansion

Management emphasizes expansion in the U.S. and China, scaling Terumo BCT’s cell therapy platforms, and rolling out digital-enabled blood-center solutions in North America and EMEA; see Revenue Streams & Business Model of Terumo.

Terumo Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔